{"id":"lutetium-177lu-chloride","rwe":[{"pmid":"32604118","year":"2020","title":"Whole-Body 177Lu-Prostate-Specific Membrane Antigen Scan Pattern With Excess Free 177Lu-Chloride in a Metastatic Castration-Resistant Prostate Cancer Patient.","finding":"","journal":"Clinical nuclear medicine","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Radiolabelling of carrier molecules","category":"indication"},{"label":"I.D.B. Radiopharmacy B.V.","category":"company"}],"phase":"marketed","safety":{"safetySignals":[{"llr":797.031,"date":"","count":2147,"signal":"Drug ineffective","source":"DrugCentral FAERS","actionTaken":"Reported 2,147 times (LLR=797)"},{"llr":563.882,"date":"","count":8,"signal":"Pemphigus","source":"DrugCentral FAERS","actionTaken":"Reported 8 times (LLR=564)"},{"llr":472.68,"date":"","count":365,"signal":"Prostatic specific antigen increased","source":"DrugCentral FAERS","actionTaken":"Reported 365 times (LLR=473)"},{"llr":465.58,"date":"","count":66,"signal":"Systemic lupus erythematosus","source":"DrugCentral FAERS","actionTaken":"Reported 66 times (LLR=466)"},{"llr":455.829,"date":"","count":16,"signal":"Hand deformity","source":"DrugCentral FAERS","actionTaken":"Reported 16 times (LLR=456)"},{"llr":452.008,"date":"","count":1296,"signal":"Cardiac failure congestive","source":"DrugCentral FAERS","actionTaken":"Reported 1,296 times (LLR=452)"},{"llr":403.219,"date":"","count":139,"signal":"Contraindicated product administered","source":"DrugCentral FAERS","actionTaken":"Reported 139 times (LLR=403)"},{"llr":381.677,"date":"","count":189,"signal":"Toxic anterior segment syndrome","source":"DrugCentral FAERS","actionTaken":"Reported 189 times (LLR=382)"},{"llr":373.327,"date":"","count":69,"signal":"Glossodynia","source":"DrugCentral FAERS","actionTaken":"Reported 69 times (LLR=373)"},{"llr":339.71,"date":"","count":8,"signal":"Anti-cyclic citrullinated peptide antibody positive","source":"DrugCentral FAERS","actionTaken":"Reported 8 times (LLR=340)"},{"llr":323.21,"date":"","count":1121,"signal":"Hypokalaemia","source":"DrugCentral FAERS","actionTaken":"Reported 1,121 times (LLR=323)"},{"llr":313.003,"date":"","count":43,"signal":"Pericarditis","source":"DrugCentral FAERS","actionTaken":"Reported 43 times (LLR=313)"},{"llr":283.887,"date":"","count":174,"signal":"Maternal exposure during pregnancy","source":"DrugCentral FAERS","actionTaken":"Reported 174 times (LLR=284)"},{"llr":279.48,"date":"","count":108,"signal":"Wound","source":"DrugCentral FAERS","actionTaken":"Reported 108 times (LLR=279)"},{"llr":264.029,"date":"","count":311,"signal":"Rheumatoid arthritis","source":"DrugCentral FAERS","actionTaken":"Reported 311 times (LLR=264)"}],"commonSideEffects":[],"contraindications":["Pregnancy, function"]},"trials":[],"aliases":[],"company":"I.D.B. Radiopharmacy B.V.","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=lutetium (177Lu) chloride","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:10:21.351354+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:10:27.033878+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T01:10:21.424169+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=lutetium (177Lu) chloride","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:10:27.487887+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL6068058/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:10:29.204745+00:00"}},"allNames":"lumark","offLabel":[],"synonyms":["lutetium (177Lu) chloride","lumark","illuzyce"],"timeline":[{"date":"2015-06-18","type":"positive","source":"DrugCentral","milestone":"EMA approval (I.D.B. Radiopharmacy B.V.)"}],"approvals":[{"date":"2015-06-18","orphan":false,"company":"I.D.B. Radiopharmacy B.V.","regulator":"EMA"}],"brandName":"Lumark","ecosystem":[{"indication":"Radiolabelling of carrier molecules","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Lumark is a small molecule radiopharmaceutical that utilizes the radioactive isotope lutetium-177 (177Lu) in its chloride form. The 177Lu isotope has a relatively long half-life of approximately 6.65 days, allowing for its use in targeted radionuclide therapy and diagnostic imaging applications."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5682","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=lutetium (177Lu) chloride","fields":["publications"],"source":"PubMed/NCBI"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T12:27:13.389199","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:10:30.936467+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"lutetium (177lu) chloride","indications":{"approved":[{"name":"Radiolabelling of carrier molecules","source":"DrugCentral","snomedId":"","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"_emaApprovals":[{"date":"2015-06-18","status":"Authorised","company":"I.D.B. Radiopharmacy B.V."}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"04M8624OXV","INN_ID":"2351","chemblId":"CHEMBL6068058","KEGG_DRUG":"D10828","DRUGBANK_ID":"DB00761","PDB_CHEM_ID":"CL","PUBCHEM_CID":"71587001"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"I.D.B. Radiopharmacy B.V.","relationship":"Original Developer"}],"publicationCount":1,"therapeuticAreas":["Other"],"biosimilarFilings":[],"originalDeveloper":"I.D.B. Radiopharmacy B.V.","recentPublications":[{"date":"2020 Oct","pmid":"32604118","title":"Whole-Body 177Lu-Prostate-Specific Membrane Antigen Scan Pattern With Excess Free 177Lu-Chloride in a Metastatic Castration-Resistant Prostate Cancer Patient.","journal":"Clinical nuclear medicine"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"I.D.B. Radiopharmacy B.V.","companyId":"i-d-b-radiopharmacy-b-v","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:10:30.936467+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":false,"score":1}}